CLYM
Climb Bio, Inc.
$12.90
-0.39 (-2.93%)
At close · Jul 2
Market Cap
$738.66M
Shares
57,260,523
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.90
Open$13.10
Day$12.43–13.49
52W$1.19–13.69
Avg vol 30d1.4M
Short int3.0M · 5.2% float · 2.0d
Short vol57%
Last earningsMay 7, 2026
DataAug 2021–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+116% above
+
Price vs 50-day avg
+17% above
◦
RSI (14)
61 · neutral
+
MACD trend
positive
+
52-week position
94% · near high
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $11 › 200d $6 — 50d above 200d
+
Institutional flow
+23% holders QoQ · +27 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
5.24% of float · ▲ +57.3% MoM · 2.0 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
80 holders — near 3-yr high, broad support
Fundamentals
Strong
+
EPS growth
+42% Y/Y
−
Free cash flow
$-54.5M
+
Balance sheet
net cash $35.7M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 3, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+116% above
Bullish
Price vs 50-day avg
+17% above
Bullish
RSI (14)
61 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
94% · near high
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +27 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.24% of float · ▲ +57.3% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
80 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $13 · 94%
52-wk high $14
vs 200-day avg +116%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLYM
this stock
Climb Bio, Inc.
|
$738.66M | +222.5% | — | — | 5.2% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLYM | +1.9% | +23.6% | +181.7% | -1.1% | +222.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +0.5% | +24.8% | +173.6% | -0.8% | +213.3% |